News headlines about ConforMIS (NASDAQ:CFMS) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. ConforMIS earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned media headlines about the medical instruments supplier an impact score of 44.8389552902488 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news stories that may have impacted Accern’s scoring:

Shares of ConforMIS (NASDAQ:CFMS) traded up $0.07 during trading on Monday, hitting $2.55. 311,569 shares of the stock traded hands, compared to its average volume of 422,834. ConforMIS has a fifty-two week low of $2.21 and a fifty-two week high of $8.72. The company has a debt-to-equity ratio of 0.52, a quick ratio of 5.38 and a current ratio of 6.19. The firm has a market cap of $109.61 and a PE ratio of -1.90.

ConforMIS (NASDAQ:CFMS) last issued its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported ($0.29) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.03. The firm had revenue of $18.40 million during the quarter, compared to analysts’ expectations of $17.55 million. ConforMIS had a negative net margin of 72.70% and a negative return on equity of 76.88%. ConforMIS’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.31) EPS. analysts expect that ConforMIS will post -1.27 earnings per share for the current year.

Several brokerages have recently issued reports on CFMS. BTIG Research restated a “hold” rating on shares of ConforMIS in a report on Thursday, November 2nd. JPMorgan Chase & Co. cut shares of ConforMIS from a “neutral” rating to an “underweight” rating in a report on Tuesday, January 2nd. Finally, Zacks Investment Research cut shares of ConforMIS from a “buy” rating to a “hold” rating in a report on Tuesday, October 31st. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. ConforMIS currently has a consensus rating of “Hold” and an average price target of $5.54.

In related news, insider David Cerveny sold 16,392 shares of the stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $3.17, for a total transaction of $51,962.64. Following the completion of the sale, the insider now owns 151,408 shares in the company, valued at approximately $479,963.36. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CTO Daniel Steines sold 15,485 shares of the stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $3.15, for a total transaction of $48,777.75. Following the sale, the chief technology officer now owns 254,652 shares of the company’s stock, valued at approximately $802,153.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 85,994 shares of company stock valued at $244,696. 9.55% of the stock is owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2018/01/08/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-conformis-cfms-stock-price.html.

ConforMIS Company Profile

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Insider Buying and Selling by Quarter for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.